

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Ebola	Ebola glycoprotein GP1; Ebola glycoprotein GP2	<p>Nonhuman primate studies suggest a cocktail of three mAbs called MB-003, which targets GP1 and GP2, could treat Ebola infection. In nonhuman primates showing symptoms of Ebola infection, MB-003 given in 3 doses 120, 170 and 250 hours after exposure resulted in survival in 3 of 7 animals. Next steps include dose optimization, pharmacology and toxicology testing.</p> <p>MB-003 is in preclinical development to treat Ebola infection.</p> <p>SciBX 6(36); doi:10.1038/scibx.2013.996 Published online Sept. 19, 2013</p>	<p>Patented by the U.S. Army Medical Research Institute of Infectious Diseases; licensed to Mapp Biopharmaceutical Inc.; available for licensing and partnering through Mapp</p>	<p>Pettitt, J. <i>et al. Sci. Transl. Med.</i>; published online Aug. 21, 2013; doi:10.1126/scitranslmed.3006608 Contact: Gene G. Olinger, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Md. e-mail: gene.g.olinger2.civ@mail.mil Contact: Larry Zeitlin, Mapp Biopharmaceutical Inc., San Diego, Calif. e-mail: larry.zeitlin@mappbio.com</p>